Published in Respir Care on December 01, 2003
Effective mucus clearance is essential for respiratory health. Am J Respir Cell Mol Biol (2006) 1.98
COPD exacerbations . 2: aetiology. Thorax (2006) 1.90
Airway mucus: From production to secretion. Am J Respir Cell Mol Biol (2006) 1.73
Human rhinovirus proteinase 2A induces TH1 and TH2 immunity in patients with chronic obstructive pulmonary disease. J Allergy Clin Immunol (2010) 1.69
Moxifloxacin versus amoxicillin/clavulanic acid in outpatient acute exacerbations of COPD: MAESTRAL results. Eur Respir J (2011) 1.68
Beyond FEV₁ in COPD: a review of patient-reported outcomes and their measurement. Int J Chron Obstruct Pulmon Dis (2012) 1.47
Particulate matter air pollution exposure: role in the development and exacerbation of chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis (2009) 1.27
The role of bronchodilator treatment in the prevention of exacerbations of COPD. Eur Respir J (2012) 1.23
Critical modifier role of membrane-cystic fibrosis transmembrane conductance regulator-dependent ceramide signaling in lung injury and emphysema. J Immunol (2010) 1.14
Critical role of CFTR-dependent lipid rafts in cigarette smoke-induced lung epithelial injury. Am J Physiol Lung Cell Mol Physiol (2011) 1.09
Factors associated with change in exacerbation frequency in COPD. Respir Res (2013) 1.08
Markers of exacerbation severity in chronic obstructive pulmonary disease. Respir Res (2006) 1.04
Neutrophilic inflammation and IL-8 levels in induced sputum of alpha-1-antitrypsin PiMZ subjects. Thorax (2005) 1.01
Role of N-acetylcysteine in the management of COPD. Int J Chron Obstruct Pulmon Dis (2006) 0.98
Examining the relationship between anxiety and depression and exacerbations of COPD which result in hospital admission: a systematic review. Int J Chron Obstruct Pulmon Dis (2014) 0.97
Tackling COPD: a multicomponent disease driven by inflammation. MedGenMed (2006) 0.95
Value of arterial blood gas analysis in patients with acute dyspnea: an observational study. Crit Care (2011) 0.95
C-reactive protein measurements as a marker of the severity of chronic obstructive pulmonary disease exacerbations. Inflammation (2013) 0.88
Differential inflammatory response to inhaled lipopolysaccharide targeted either to the airways or the alveoli in man. PLoS One (2012) 0.88
Relationship between the GOLD combined COPD assessment staging system and bacterial isolation. Int J Chron Obstruct Pulmon Dis (2014) 0.87
Prediction and course of symptoms and lung function around an exacerbation in chronic obstructive pulmonary disease. Respir Res (2012) 0.86
Effectiveness and cost-effectiveness of early assisted discharge for chronic obstructive pulmonary disease exacerbations: the design of a randomised controlled trial. BMC Public Health (2010) 0.86
Symptoms and impact of COPD assessed by an electronic diary in patients with moderate-to-severe COPD: psychometric results from the SHINE study. Int J Chron Obstruct Pulmon Dis (2015) 0.84
Utility of the CAT in the therapy assessment of COPD exacerbations in China. BMC Pulm Med (2014) 0.84
Pathophysiology of viral-induced exacerbations of COPD. Int J Chron Obstruct Pulmon Dis (2007) 0.84
Systemic cytokine signaling via IL-17 in smokers with obstructive pulmonary disease: a link to bacterial colonization? Int J Chron Obstruct Pulmon Dis (2015) 0.83
The role of interleukin-1 and interleukin-18 in pro-inflammatory and anti-viral responses to rhinovirus in primary bronchial epithelial cells. PLoS One (2013) 0.83
A pilot study of the impact of high-frequency chest wall oscillation in chronic obstructive pulmonary disease patients with mucus hypersecretion. Int J Chron Obstruct Pulmon Dis (2011) 0.83
Resolvin D1 attenuates polyinosinic-polycytidylic acid-induced inflammatory signaling in human airway epithelial cells via TAK1. J Immunol (2014) 0.82
Exacerbations in patients with chronic obstructive pulmonary disease receiving physical therapy: a cohort-nested randomised controlled trial. BMC Pulm Med (2014) 0.82
Hochu-ekki-to inhibits rhinovirus infection in human tracheal epithelial cells. Br J Pharmacol (2007) 0.79
History of pneumonia is a strong risk factor for chronic obstructive pulmonary disease (COPD) exacerbation in South Korea: the Epidemiologic review and Prospective Observation of COPD and Health in Korea (EPOCH) study. J Thorac Dis (2015) 0.79
Value of serum and induced sputum surfactant protein-D in chronic obstructive pulmonary disease. Multidiscip Respir Med (2013) 0.79
Computerised Analysis of Telemonitored Respiratory Sounds for Predicting Acute Exacerbations of COPD. Sensors (Basel) (2015) 0.78
Relationship between frequency, length, and treatment outcome of exacerbations to baseline lung function and lung density in alpha-1 antitrypsin-deficient COPD. Int J Chron Obstruct Pulmon Dis (2012) 0.78
Antibiotics active against Chlamydia do not reduce the risk of myocardial infarction. Eur J Clin Pharmacol (2005) 0.78
The prevalence of pulmonary embolism among patients suffering from acute exacerbations of chronic obstructive pulmonary disease. Emerg Radiol (2014) 0.78
Alterations in the expression of the NF-κB family member RelB as a novel marker of cardiovascular outcomes during acute exacerbations of chronic obstructive pulmonary disease. PLoS One (2014) 0.78
Trigger factors in asthma and chronic obstructive pulmonary disease: a single-centre cross-sectional survey. Singapore Med J (2015) 0.77
Three-month treatment response and exacerbation in chronic obstructive pulmonary disease. J Korean Med Sci (2014) 0.77
Depression Is Associated with Readmission for Acute Exacerbation of Chronic Obstructive Pulmonary Disease. Ann Am Thorac Soc (2016) 0.77
Incidence and risk factors of exacerbations among COPD patients in primary health care: APMPOC study. BMC Public Health (2009) 0.76
Cadmium attenuates the macrophage response to LPS through inhibition of the NF-κB pathway. Am J Physiol Lung Cell Mol Physiol (2016) 0.76
Risk of exacerbation in chronic obstructive pulmonary disease: a primary care retrospective cohort study. BMC Fam Pract (2015) 0.76
Comparison and optimal use of fixed combinations in the management of COPD. Int J Chron Obstruct Pulmon Dis (2007) 0.76
Systemic signs of neutrophil mobilization during clinically stable periods and during exacerbations in smokers with obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis (2015) 0.76
Differential Effects of p38, MAPK, PI3K or Rho Kinase Inhibitors on Bacterial Phagocytosis and Efferocytosis by Macrophages in COPD. PLoS One (2016) 0.75
Interleukin-22 protects against non-typeable Haemophilus influenzae infection: alteration during chronic obstructive pulmonary disease. Mucosal Immunol (2016) 0.75
Mortality rates for chronic lower respiratory diseases in Italy from 1979 to 2010: an age-period-cohort analysis. ERJ Open Res (2016) 0.75
Clinical and Immunological Benefits of OM-85 Bacterial Lysate in Patients with Allergic Rhinitis, Asthma, and COPD and Recurrent Respiratory Infections. Lung (2016) 0.75
Theaflavins extracted from black tea inhibit airway mucous hypersecretion induced by cigarette smoke in rats. Inflammation (2012) 0.75
Prognostic utility of admission cell-free DNA levels in patients with chronic obstructive pulmonary disease exacerbations. Int J Chron Obstruct Pulmon Dis (2016) 0.75
Day of Surgery Admission in Total Joint Arthroplasty: Why Are Surgeries Cancelled? An Analysis of 3195 Planned Procedures and 114 Cancellations. Adv Orthop (2016) 0.75
The recent advances of phenotypes in acute exacerbations of COPD. Int J Chron Obstruct Pulmon Dis (2017) 0.75
The optimum timing to wean invasive ventilation for patients with AECOPD or COPD with pulmonary infection. Int J Chron Obstruct Pulmon Dis (2016) 0.75
Acute exacerbation of COPD: is it the "stroke of the lungs"? Int J Chron Obstruct Pulmon Dis (2016) 0.75
COPD exacerbations by disease severity in England. Int J Chron Obstruct Pulmon Dis (2016) 0.75
Increased parasympathetic cardiac modulation in patients with acute exacerbation of COPD: how should we interpret it? Int J Chron Obstruct Pulmon Dis (2017) 0.75
The Burden of Illness Related to Chronic Obstructive Pulmonary Disease Exacerbations in Québec, Canada. Can Respir J (2017) 0.75
Early therapy improves outcomes of exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2004) 4.87
Temporal clustering of exacerbations in chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2008) 4.73
Usefulness of the Chronic Obstructive Pulmonary Disease Assessment Test to evaluate severity of COPD exacerbations. Am J Respir Crit Care Med (2012) 3.09
Use of plasma biomarkers at exacerbation of chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2006) 2.80
Derivation and validation of a composite index of severity in chronic obstructive pulmonary disease: the DOSE Index. Am J Respir Crit Care Med (2009) 2.17
Effect of interactions between lower airway bacterial and rhinoviral infection in exacerbations of COPD. Chest (2006) 2.06
Bronchiectasis, exacerbation indices, and inflammation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2004) 1.90
Airway bacterial load and FEV1 decline in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2003) 1.85
Cardiovascular risk, myocardial injury, and exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2013) 1.77
Systemic and upper and lower airway inflammation at exacerbation of chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2005) 1.75
Determinants and impact of fatigue in patients with chronic obstructive pulmonary disease. Respir Med (2008) 1.68
Detection and severity grading of COPD exacerbations using the exacerbations of chronic pulmonary disease tool (EXACT). Eur Respir J (2013) 1.62
Mechanisms and impact of the frequent exacerbator phenotype in chronic obstructive pulmonary disease. BMC Med (2013) 1.62
C-reactive protein: does it predict mortality? Am J Respir Crit Care Med (2007) 1.47
Changes in prevalence and load of airway bacteria using quantitative PCR in stable and exacerbated COPD. Thorax (2012) 1.42
Respiratory syncytial virus, airway inflammation, and FEV1 decline in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2006) 1.40
Time course and pattern of COPD exacerbation onset. Thorax (2011) 1.30
A computer simulation model of the natural history and economic impact of chronic obstructive pulmonary disease. Value Health (2004) 1.17
Relationships among bacteria, upper airway, lower airway, and systemic inflammation in COPD. Chest (2005) 1.07
Serum IP-10 as a biomarker of human rhinovirus infection at exacerbation of COPD. Chest (2009) 1.01
Domiciliary pulse-oximetry at exacerbation of chronic obstructive pulmonary disease: prospective pilot study. BMC Pulm Med (2010) 0.99
25-hydroxyvitamin D deficiency, exacerbation frequency and human rhinovirus exacerbations in chronic obstructive pulmonary disease. BMC Pulm Med (2012) 0.93
Upper airway symptoms and quality of life in chronic obstructive pulmonary disease (COPD). Respir Med (2004) 0.92
Natural history of successive COPD exacerbations. Thorax (2012) 0.87
Inflammatory thresholds and the species-specific effects of colonising bacteria in stable chronic obstructive pulmonary disease. Respir Res (2014) 0.86
Use of long-term antibiotic treatment in COPD patients in the UK: a retrospective cohort study. Prim Care Respir J (2013) 0.84
Relationship between chronic nasal and respiratory symptoms in patients with COPD. Respir Med (2003) 0.84
Daily activity during stability and exacerbation of chronic obstructive pulmonary disease. BMC Pulm Med (2014) 0.83
Exacerbation of chronic obstructive pulmonary disease: pan-airway and systemic inflammatory indices. Proc Am Thorac Soc (2006) 0.79
Winter mortality in elderly people in Britain: action on outdoor cold stress is needed to reduce winter mortality. BMJ (2004) 0.78
Heat acclimatization and sunshine cause false indications of mortality due to ozone. Environ Res (2005) 0.78
Airway and systemic inflammation and decline in lung function in patients with COPD. 2005. Chest (2009) 0.77
Prednisone for chronic obstructive pulmonary disease. N Engl J Med (2003) 0.75
SERPINA1 11478G→A variant, serum α1-antitrypsin, exacerbation frequency and FEV1 decline in COPD. Thorax (2011) 0.75
Exacerbations in non-COPD patients: recognition? Thorax (2014) 0.75
The CODEX index: a collection or digest of laws: a code. Chest (2014) 0.75